Canada Androgenetic Alopecia Market Insights Forecasts to 2033

• The Canada Androgenetic Alopecia Market Size was valued at USD 89.5 Million in 2023.
• The Market is Growing at a CAGR of 9.44% from 2023 to 2033
• The Canada Androgenetic Alopecia Market Size is Expected to reach USD 220.5 Million by 2033

The Canada Androgenetic Alopecia Market Size is anticipated to exceed USD 220.5 Million by 2033, Growing at a CAGR of 9.44% from 2023 to 2033. The increasing prevalence of androgenetic alopecia, high economic development, and improved healthcare facilities are driving the growth of the androgenetic alopecia market in the Canada.     

Market Overview

Androgenetic alopecia (AGA) is a genetically predetermined disorder caused due to an overreaction to androgens. It is also known as pattern hair loss characterized by progressive hair loss on the scalp. Males experience the most noticeable hair loss in the vertex and frontotemporal areas, whereas females typically maintain their frontal hairline while undergoing diffuse apical hair thinning, which makes the anterior portion of the hair appear wider. Advancements in the treatment of androgenetic alopecia and the creation of precise drug designs that may increase efficacy and safety are augmenting market growth opportunities. Further, the introduction of digital technologies that have facilitated remote monitoring and management of AGA patients provide better choices for treating androgenetic alopecia. 

Report Coverage

This research report categorizes the market for the Canada androgenetic alopecia market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Canada androgenetic alopecia market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Canada androgenetic alopecia market.

Driving Factors

The increasing prevalence of androgenetic alopecia among male and female are driving the market. The introduction of numerous cutting-edge, contemporary treatments for hair loss in healthcare facilities is driving the market growth. For instance, PRP (platelet-rich plasma) therapy and laser treatments are customized based on the causes of hair loss.

Restraining Factors

The high treatment cost of androgenetic alopecia is challenging the androgenetic alopecia market. Further, the side effects associated with the treatment of AGA are hindering the market growth.

Market Segmentation

The Canada Androgenetic Alopecia Market share is classified into gender, treatment, end-use, and sales channel.

• The male segment dominated the market with the largest market share during the forecast period.

The Canada androgenetic alopecia market is segmented by gender into male and female. Among these, the male segment dominated the market with the largest market share during the forecast period. By the age of fifty, thirty to fifty percent of males suffer from male androgenetic alopecia (MAA), the most prevalent kind of hair loss in men. The surging development of new products for treatment and the high prevalence of AGA are driving the market.

• The pharmaceuticals segment accounted for the largest market share during the forecast period.

The Canada androgenetic alopecia market is segmented by treatment into pharmaceuticals and devices. Among these, the pharmaceuticals segment accounted for the largest market share during the forecast period. The most often used treatments for this illness are minoxidil and 5-alpha reductase inhibitors. The availability of treatment options and an increasing number of research & development are driving the market.

• The dermatology clinics segment dominated the Canada androgenetic alopecia market with the largest market share in 2023.       

Based on the end-use, the Canada androgenetic alopecia market is divided into dermatology clinics and homecare settings. Among these, the dermatology clinics segment dominated the Canada androgenetic alopecia market with the largest market share in 2023. Variety of treatments are provided in dermatology clinics including low-laser therapy, hair transplant, platelet rich plasma and nano fat treatment. The increased awareness about prescription medication and advanced therapies for the treatment are driving the market.

• The prescriptions segment held the largest revenue share of the Canada androgenetic alopecia market in 2023.

Based on the sales channel, the Canada androgenetic alopecia market is divided into prescriptions and OTC. Among these, the prescriptions segment held the largest revenue share of the Canada androgenetic alopecia market in 2023. A number of prescription medications are offered for hair regeneration in people with androgenetic alopecia, such as fluocinolone acetonide, betamethasone dipropionate, and minoxidil. The increasing product launches and clinical trials are expected to drive the market growth.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Canada androgenetic alopecia market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Cipla Limited
• Aclaris Therapeutics, Inc.
• PureTech
• Vita-Cos-Med Klett-Loch GmbH
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In June 2024, Triple Hair Group, a Montréal, Canada-based company that specializes in the development of innovative treatments for androgenic alopecia, raised $4M in funding.

Market Segment

This study forecasts revenue at Canada, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Canada Androgenetic Alopecia Market based on the below-mentioned segments:

Canada Androgenetic Alopecia Market, By Gender

• Male
• Female

Canada Androgenetic Alopecia Market, By Treatment

• Pharmaceuticals
• Devices

Canada Androgenetic Alopecia Market, By End-use

• Dermatology Clinics
• Homecare Settings

Canada Androgenetic Alopecia Market, By Sales Channel

• Prescriptions
• OTC